A5081486421- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Diet and metabolism studies
- Mental Health and Psychiatry
- Functional Brain Connectivity Studies
- Tryptophan and brain disorders
- Neuroscience and Neuropharmacology Research
- Treatment of Major Depression
- Electroconvulsive Therapy Studies
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Receptor Mechanisms and Signaling
- Attention Deficit Hyperactivity Disorder
- Maternal Mental Health During Pregnancy and Postpartum
- Psychosomatic Disorders and Their Treatments
- Cardiac electrophysiology and arrhythmias
- Obsessive-Compulsive Spectrum Disorders
- Neural and Behavioral Psychology Studies
- Epilepsy research and treatment
- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Music Perception
- Pharmacological Effects and Toxicity Studies
- Autoimmune Neurological Disorders and Treatments
- Neurotransmitter Receptor Influence on Behavior
- Cell death mechanisms and regulation
Universitat de Barcelona
2014-2025
Hospital Clínic de Barcelona
2015-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2014-2025
Centro de Investigación Biomédica en Red de Salud Mental
2014-2025
Instituto de Salud Carlos III
2022-2025
Institució Catalana de Recerca i Estudis Avançats
2021-2022
University of Pennsylvania
2022
Medical Research Network
2017-2021
Biomedical Research Institute
2021
Neurosciences Institute
2021
Some studies suggest individuals with schizophrenia have an increased risk of diabetes prior to antipsychotic use. Small sample sizes and the potential for confounding by hypercortisolaemia decreased confidence in those results.To examine diabetes-related factors newly diagnosed, antipsychotic-naive people non-affective psychosis.Participants psychosis (the group; n = 50) matched controls control were given a 2 h oral glucose tolerance test. Fasting concentrations also determined...
To report the neuropsychiatric features and frequency of NMDA receptor (NMDAR) other neuronal immunoglobulin G antibodies in patients with first episode psychosis (FEP) to assess performance reported warning signs criteria for autoimmune (AP).This was a prospective observational study FEP assessed symptoms, serum CSF (brain immunohistochemistry, cell-based assays, live neurons), AP. Previous series were reviewed.One hundred five included; their median age 30 (range 14-75) years, 44 (42%)...
<h3>Background and Objectives</h3> An important challenge in diagnosing anti–NMDA receptor (NMDAR) encephalitis (NMDARe) is differentiating it from a first episode of psychosis (FEP) caused by psychiatric disease (pFEP). CSF antibody testing distinguishes these diseases, but spinal taps are difficult to obtain facilities. A separate problem the lack biomarkers NMDARe severity outcome. Here we assessed performance neurofilament light chain (NfL) settings. <h3>Methods</h3> In this...
The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous medication. Patients symptomatically stable, but considered to require a treatment change, received 25 mg RLAI (increased 37.5 50 mg, if necessary) every 2 weeks for 6 months. Assessments included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression–Severity (CGI-S),...
Introduction: Recent studies suggest that in addition to factors such as treatment side effects, suicide, and poor health habits, people with schizophrenia may have an increased risk of diabetes prior antipsychotic treatment. Diabetes is associated pulse pressure (PP) a shortened telomere. We tested the hypothesis treatment, related disorders are telomere, well PP. Methods: Telomere content (which highly correlated telomere length) PP were measured newly diagnosed, antipsychotic-naive...
Article AbstractBackground: The aim of this study was to evaluate the efficacy and safety risperidone in treatment patients with delirium. Method: We conducted a prospective, multicenter, observational 7-day 5 university general hospitals. Sixty-four (62.5% male ; mean age: 67.3 ± 11.4 years) hospitalized due medical condition who met criteria for delirium according DSM-IV were enrolled study. Fifty-six received 7 days or less, while 8 continued more than days. Effectiveness assessed using...
In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored patients acute symptoms of schizophrenia following switching from previously unsuccessful oral antipsychotics. This pragmatic was conducted a large, more representative sample the general population compared to randomized controlled pivotal trials, specifically mimic...
(1) Background: The cognitive reserve (CR) concept has not been precisely defined in severe mental disorders and estimated using heterogeneous methods. This study aims to investigate develop the psychometric properties of Cognitive Reserve Assessment Scale Health (CRASH), an instrument designed measure CR people with illness; (2) Methods: 100 patients illness (non-affective psychoses affective disorders) 66 healthy controls were included. internal consistency convergent validity CRASH...
Observational studies have reported earlier onset of psychosis in schizophrenic patients with a history cannabis use. Earlier age schizophrenia has been associated poorer outcome. We aimed to examine whether use determined an sample first episode patients, area one Europe's highest rates use.116 subjects and subsequent diagnosis (after 12-month follow-up) were included Age at antipsychotic treatment (A1T) was used as proxy for onset, acted dependent variable the statistical analysis....
Abstract Background: Around 30% of patients with schizophrenia are considered treatment resistant (TRS). Only around 40% TRS respond to clozapine. Long acting injectable antipsychotics could be a useful augmentation strategy for nonresponders. Methods: We conducted multicenter, observational, naturalistic, retrospective, 6-month mirror-image study evaluate the efficacy and tolerability clozapine paliperidone palmitate association in 50 other psychotic disorders. Clinical outcomes side...
The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients the early phases schizophrenia schizoaffective disorders (≤ 3 years). Patients who required a treatment change received RLAI (2-weekly gluteal injections 25, 37.5 or 50mg, per clinical judgement), without an oral run-in phase. A total 382 were included this 6-month open-label study; 73% completed study. 84% had with median duration 1.0 year since diagnosis. Previous medications mainly atypical...